Central Trust Company’s BioLife Solutions BLFS Stock Holding History

Central Trust Company’s Portfolio BLFS Stock Details BLFS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13	Closed	-$249	–	1588
2026 Q1	$249	Buy	+13	New	+$287	﹤0.01%	1538

Other funds holding BLFS

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Central Trust Company's BLFS Position: Q2 2026 in Review

Central Trust Company sold out of BioLife Solutions (BLFS) in Q2 2026, closing a stake of 13 shares — an estimated $249 sold.

Central Trust Company first reported a position in BLFS in Q1 2026 and held it in 1 quarter. The position peaked at $249 in Q1 2026. 217 funds tracked by Wall St. Rank hold BLFS as of Q2 2026.

Central Trust Company reported no remaining BioLife Solutions position as of Q2 2026 after selling out during the quarter.
Central Trust Company sold 13 BioLife Solutions shares in Q2 2026, an estimated $249.
Central Trust Company first reported a position in BioLife Solutions in Q1 2026 and held it in 1 quarter.
Central Trust Company's BioLife Solutions position peaked at $249 in Q1 2026.
217 funds tracked by Wall St. Rank held BioLife Solutions as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.